Key result
Abciximab binds GP IIb/IIIa and αvβ3 with equal affinity, dynamically redistributing between both integrins.
Why the study?
Abciximab was initially developed to block GP IIb/IIIa receptors on platelets but also binds with equivalent affinity to alpha(v)beta3 integrins, warranting detailed characterization of this interaction.
Comparison
Binding affinity and functional blockade of GP IIb/IIIa versus alpha(v)beta3 integrins by abciximab
Design
In vitro characterization study
Authors
Loading...
Abciximab's dual αvβ3/GPIIb/IIIa blockade may contribute to PCI benefits; leaves open whether αvβ3 adds incremental value.
Tam et al. (1998) studied this question. Abciximab was evaluated on Binding affinity and functional blockade of GP IIb/IIIa and αvβ3 integrins. Abciximab binds with equivalent affinity to both GP IIb/IIIa and αvβ3 integrins and redistributes between the two receptors in vitro.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: